These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31229334)

  • 1. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
    Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
    Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of von Willebrand Disease.
    Curnow J; Pasalic L; Favaloro EJ
    Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting von Willebrand disease: the current status and future directions of management therapies.
    Franchini M; Focosi D
    Expert Rev Hematol; 2023; 16(11):871-878. PubMed ID: 37800892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement Therapy in Patients with Von Willebrand Disease-Indications and Monitoring.
    Nowak-Göttl U; Miesbach W; Koscielny J; Dempfle CE; Maegele M; Prondzinski MVD; Westrup D; Spannagl M
    Hamostaseologie; 2019 Nov; 39(4):326-338. PubMed ID: 31364093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.